Masaya Tachibana

发表

Population Pharmacokinetics of Edoxaban in Japanese Atrial Fibrillation Patients With Severe Renal Impairment

Takako Shimizu, K. Yoshihara, Tetsuya Kimura, 2017, Clinical pharmacology in drug development.

Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation

E. Antman, R. Giugliano, S. Zhou, 2012, Thrombosis and Haemostasis.

Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers

J. Mendell, S. Kunitada, Masaya Tachibana, 2011, Journal of clinical pharmacology.

Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers

H. Masumoto, K. Ogata, S. Kunitada, 2010, Journal of clinical pharmacology.

Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan

Mark Lee, F. LaCreta, M. Abutarif, 2021, Clinical and translational science.

Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia

H. Ohno, T. Miyamoto, S. Kasahara, 2022, International Journal of Hematology.

Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study

Toshio Shimizu, S. Sakajiri, T. Koyama, 2021, Cancer science.

First-in-human study of DS-6051b in patients (pts) with advanced solid tumors (AST) conducted in the US.

P. Jänne, A. Shaw, S. Ou, 2018 .

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors

P. Jänne, Qinying Zhao, H. Wakelee, 2020, Clinical Cancer Research.

The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas

F. Yamasaki, K. Sugiyama, Hideo Nakamura, 2022, Neuro-oncology.

An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma

A. Utsunomiya, K. Izutsu, K. Tobinai, 2022, Blood.

Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours

I. Puzanov, K. Papadopoulos, J. Strickler, 2018, British journal of clinical pharmacology.

Pharmacokinetics, Tissue Distribution, and Excretion of Sitafloxacin, a New Fluoroquinolone Antibiotic, in Rats, Dogs, and Monkeys

Makoto Tanaka, Masaya Tachibana, O. Okazaki, 2004, Arzneimittelforschung.

Predictability of Idiosyncratic Drug Toxicity Risk for Carboxylic Acid-Containing Drugs Based on the Chemical Stability of Acyl Glucuronide

Osamu Okazaki, Atsushi Kurihara, Kengo Watanabe, 2010, Drug Metabolism and Disposition.

Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open‐label, drug–drug interaction study

H. Zahir, Ling He, G. Atiee, 2018, British journal of clinical pharmacology.

Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia

H. Ohno, T. Miyamoto, S. Kasahara, 2022, International journal of hematology.

ACYL GLUCURONIDATION OF FLUOROQUINOLONE ANTIBIOTICS BY THE UDP-GLUCURONOSYLTRANSFERASE 1A SUBFAMILY IN HUMAN LIVER MICROSOMES

Y. Masubuchi, T. Horie, Makoto Tanaka, 2005, Drug Metabolism and Disposition.

Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive IDH1 mutant gliomas.

F. Yamasaki, K. Sugiyama, Y. Muragaki, 2019, Journal of Clinical Oncology.

Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers

H. Masumoto, K. Ogata, S. Kunitada, 2010, Journal of clinical pharmacology.